This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Amsterdam, R. G.M. Articles by Meuleman, D. G. Search for Related Content PubMed PubMed Citation Articles by van Amsterdam, R. G.M. Articles by Meuleman, D. G.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:495-503.)
© 1995 American Heart Association, Inc.

Articles

Synthetic Analogues of the Antithrombin III– Binding Pentasaccharide Sequence of Heparin

Prediction of In Vivo Residence Times

Ronald G.M. van Amsterdam; Gerard M.T. Vogel; Arie Visser; Wim J. Kop; Marc T. Buiting; Dirk G. Meuleman

From the Scientific Development Group, N.V. Organon, Oss, the Netherlands.

Correspondence to R.G.M. van Amsterdam, Department of Vascular Pharmacology, N.V. Organon, PO Box 20, NL-5340 BH Oss, the Netherlands.

Abstract The synthetic pentasaccharide Org 31540/SR 90107A represents the antithrombin III (ATIII) binding region of heparin and accelerates the ATIII-mediated inhibition of coagulation factor Xa. This compound and 15 structural analogues with ATIII binding constants (K_d) ranging from 2.7 to 2600 nmol/L were compared for their plasma elimination in rats as measured from their factor Xa inhibiting activity. After administration of a low dose (100 nmol/kg body wt IV), each pentasaccharide showed a characteristic plasma half-life varying from a minimum of 0.3 hour for pentasaccharides with low affinity for ATIII to 10.9 hours for pentasaccharides with high affinity for the protein. The latter value was close to the half-life measured for radioiodinated rat ATIII (11.8 hours). We hypothesized that the elimination half-life of pentasaccharides is markedly extended by ATIII binding, of which the extent is governed by the K_d of the complex. The following observations support this hypothesis. The low-dose, low-affinity pentasaccharides were almost fully recovered in the urine without having lost anti–factor Xa activity, whereas compounds with high ATIII binding affinity were only partly recovered in the urine. With a high dose (500 nmol/kg body wt), a rapid plasma clearance of pentasaccharide was observed until a concentration similar to that of endogenous ATIII was reached, in accordance with their expected 1:1 stoichiometric interaction. The elimination half-life was similar to that of the low dose. The relation between K_d values and plasma half-lives could be explained by assuming rapid clearance of free and coclearance of ATIII-bound pentasaccharide with the protein. We applied the plasma ATIII concentration (3.5 µmol/L), the half-life of ATIII (11.8 hours), the half-life of unbound pentasaccharides (<10 minutes), and the K_d values and concluded that highly specific binding to ATIII in the circulation governs the presented straightforward pharmacological profile for the pentasaccharides.

Key Words: antithrombosis • pentasaccharides • in vivo residence • antithrombin III • rat

This article has been cited by other articles:

				K. Yamashiro, J. Kiryu, A. Tsujikawa, M. Honjo, A. Nonaka, K. Miyamoto, Y. Honda, H. Tanihara, and Y. Ogura Inhibitory Effects of Antithrombin III against Leukocyte Rolling and Infiltration during Endotoxin-Induced Uveitis in Rats Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1553 - 1560. [Abstract] [Full Text]

				J.M. Herbert, J.P. Herault, A. Bernat, R.G.M. van Amsterdam, J.C. Lormeau, M. Petitou, C. van Boeckel, P. Hoffmann, and D.G. Meuleman Biochemical and Pharmacological Properties of SANORG 34006, a Potent and Long-Acting Synthetic Pentasaccharide Blood, June 1, 1998; 91(11): 4197 - 4205. [Abstract] [Full Text] [PDF]

				J.M. Herbert, J.P. Herault, A. Bernat, R.G.M. van Amsterdam, G.M.T. Vogel, J.C. Lormeau, M. Petitou, and D.G. Meuleman Biochemical and Pharmacological Properties of SANORG 32701: Comparison With the `Synthetic Pentasaccharide' (SR 90107/ORG 31540) and Standard Heparin Circ. Res., September 1, 1996; 79(3): 590 - 600. [Abstract] [Full Text]